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http://www.biomedcentral.com/1471-244X/14/203RESEARCH ARTICLE Open AccessAssociation of serum leptin and ghrelin with
depressive symptoms in a Japanese working
population: a cross-sectional study
Shamima Akter1*, Ngoc Minh Pham1, Akiko Nanri1, Kayo Kurotani1, Keisuke Kuwahara1, Felice N Jacka2,
Kazuki Yasuda3, Masao Sato4 and Tetsuya Mizoue1Abstract
Background: Leptin and ghrelin have been implicated in the pathogenesis of major depression. However,
evidence is lacking among apparently healthy people. This study examined the relationship of these appetite
hormones to depressive symptoms in a Japanese working population.
Methods: A cross-sectional study was conducted in 2009 among 497 Japanese employees (287 men and 210
women) aged 20–68 years. Fasting serum leptin and ghrelin levels were measured using a Luminex suspension
bead-based multiplexed array. Depressive symptoms were assessed using the Center for Epidemiologic Studies
Depression (CES-D) scale. Logistic regression analysis was performed to estimate odds ratio (OR) and 95% confidence
interval (CI) for depressive symptoms with adjustment for potential confounders.
Results: The prevalence of depressive symptoms (CES-D ≥16) was 26.5% and 33.3% among men and women,
respectively. Women in the middle and highest tertiles of leptin levels showed lower odds for depressive symptoms
compared with those in the lowest level, although the trend association was not statistically significant (Ptrend = 0.14).
Higher ghrelin levels were associated with increased odds for depressive symptoms in women (Ptrend = 0.02). The
multivariable adjusted OR (95% CI) of having depressive symptoms for the lowest through highest tertiles of ghrelin
levels were 1.00 (reference), 1.71 (0.76 − 3.86), and 2.69 (1.16 − 6.28), respectively. Neither leptin nor ghrelin was
associated with depressive symptoms in men.
Conclusions: Results suggest that lower leptin and higher ghrelin levels may be related to higher prevalence of
depressive status among Japanese women.
Keywords: Depressive symptoms, Serum leptin, Serum ghrelin, JapaneseBackground
Depression is an important public health issue, affecting
approximately 350 million people worldwide, and is a sig-
nificant contributor to the global burden of disease [1,2].
It is an illness that impairs an individual’s ability to func-
tion at work or cope with daily life [3,4]. At its worst, de-
pression can lead to suicide, which is responsible for the
loss of approximately one million lives every year [2]. In
Japan, the number of patients identified with depression* Correspondence: samimarub@ri.ncgm.go.jp
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unless otherwise stated.has been increasing [5] and Japan has one of the
world’s highest suicide rates [6]. New insights into the
pathogenesis of depression to support the development of
preventive strategies for this illness are therefore essential.
Leptin, an anorexigenic hormone produced by adipose
tissue, regulates food intake and body weight [7,8], while
ghrelin, an orexigenic hormone produced mainly in the
stomach, also plays a role in regulating appetite, weight
and body fat [8,9]. These hormones have opposite effects,
not only on regulating appetite and body weight, but also
on mood and stress pathways. In animal models of
depression, administration of leptin has been shown to
improve depressive behaviors and exert antidepressant-like
effects [10,11]. Similarly, a potential role of ghrelin in thetd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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stress increases ghrelin secretion in rats [13] and central
ghrelin administration increases anxiety and depressive-like
behaviours [14].
Appetite and food intake are often altered in patients
with major depression. Although weight loss has been
recognized as a typical sign of depression, weight gain
has also been observed [15]. Chronic stress or atypical
depression may cause weight gain through increased
ingestion of calorie dense foods [16]. In addition, some
anti-depressive drugs are known to induce weight gain
[17]. Given important roles of leptin and ghrelin in the
regulation of appetite and weight, depressive status as
well as medication for depression may also influence the
levels of these hormones.
Several neural pathways linking leptin and ghrelin to
mental disorders have been suggested. Leptin may have a
role in modulating monoamine neurotransmission [18,19].
Ob/ob mice lacking leptin had lower dopamine release and
decreased concentrations of tyrosine hydroxylase, the rate
limiting enzyme in dopamine synthesis, in the nucleas
accumbens, and these effects were reversed by leptin
treatment [18]. Hyperactivity of the hypothalamic-pituitary-
adrenal (HPA) axis is a common feature of depression [20]
and accumulating evidence suggests that leptin reduces
HPA activity [21,22]. Neurotrophic actions of leptin may be
another mechanism explaining the relationship with
depressive disorders. In animal studies, leptin has been
shown to reduce depressive behaviors through the
upregulation of brain-derived neurotropic factor in
the hippocampus [23]. In contrast, ghrelin suppresses
serotonin neurotransmission [24] and increases HPA axis
activity [25,26]. Ghrelin’s suppressive effect on the central
release of monoamines and stimulatory action on the
HPA axis suggest that rising ghrelin may contribute
to the mechanisms responsible for the development
of depression.
Several studies in humans have examined the association
between leptin and depression, but their results are
inconsistent. Some clinical studies have reported lower
levels of leptin among depressed individuals [27-31] and
suicide attempters [32], while others have found either no
difference [33] or even higher blood levels of leptin in
depressed individuals [34-36], as compared with healthy
controls. Inconsistent findings have also been observed
regarding the association between ghrelin levels and
depression [27,30,37-39] and suicide attempters [40]. The
results of these clinical studies may reflect changes of
weight and appetite as a result of depression [15,33]. Only
two studies, to our knowledge, have investigated the
relationship between circulating leptin levels and
depression in the general population: one in women only
[41] and another in elderly men and women [42].
Moreover, although some data suggest racial differencesin blood levels of leptin and ghrelin [43,44], studies on this
issue have been limited to Westerners. Similarly, given a
large difference in blood leptin and ghrelin levels between
men and women [31,37,42], there may be a sex difference
in the association between these hormones and depres-
sion. Here, we examined the association of serum leptin
and ghrelin levels and depressive symptoms among
Japanese men and women.Methods
Study procedure and subjects
This study was conducted in July and November 2009
among employees of two municipal offices in northeastern
Kyushu, Japan, as described elsewhere [45]. At the time of
the periodic health examination, all full time workers
(n = 605), except those on long sick or maternity leave, were
invited to participate in this study. Participants were asked
to fill in the survey questionnaires beforehand, which were
checked by research staff for completeness and, where
necessary, clarified by questioning the subjects during the
examination. Data were also obtained from routine health
checkup, including anthropometric measurements, bio-
chemical data, and information about medical history,
smoking, and alcohol drinking. Blood and urine specimens
were also collected. The Ethics Committee of the National
Center for Global Health and Medicine, Japan, approved
the study and written informed consent was obtained from
all subjects before the survey.
Of 605 eligible employees, 567 subjects (325 men and
242 women) aged 20–68 years participated in the survey
(response rate 94%). We excluded 32 subjects with a
history of diabetes, cardiovascular disease, or cancer. We
further excluded 22 subjects without leptin and ghrelin
measurement and 25 subjects whose blood sample was
not obtained in fasting status. Some subjects fell into
more than one exclusion criteria. Finally, 497 subjects
(287 men and 210 women) remained for this study.Depressive symptoms
Depressive symptoms were assessed with the Japanese
version [46] of the Center for Epidemiologic Studies
Depression (CES-D) scale [47]. This scale consists of
20 questions addressing 6 symptoms of depression
experienced by participants during the preceding week:
depressed mood, feelings of guilt or worthlessness,
helplessness or hopelessness, psychomotor retardation,
loss of appetite, and sleep disorders. Each question is
scored on a scale of 0–3 according to the frequency
of the symptom, and the total score ranges from 0 to 60.
The criterion validity of the CES-D scale has been well
established both in Western [47] and Japanese [46] sub-
jects. Depressive symptoms were defined as present when
subjects had a CES-D score of ≥16. Another cutoff value
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that may be more suitable for Japanese was also used [48].
Blood measurements
Blood samples were obtained after an overnight fast
mostly in the morning between 8:30 and 12:00 a.m. Venus
blood (7 mL) was drawn in tube (without addition of
protease inhibitors) and then taken in a cooler box to a
laboratory. The blood was centrifuged for 10 minutes and
was divided into a maximum of six tubes (0.5 mL each)
at –80°C or –20°C until analysis. About 15 μL of serum
was used to analyze leptin and ghrelin. To quantify serum
concentrations of leptin and ghrelin, a Luminex suspen-
sion bead-based multiplexed array was performed using
Bio-Plex 3D suspension array system and Bio-Plex Pro
human diabetes assay panel (Bio-Rad Laboratories,
Hercules, CA). The intra-assay coefficients of variation
were 11% for leptin and 5% for ghrelin.
Other variables
Body height was measured to the nearest 0.1 cm with
the subjects standing without shoes. Body weight in light
clothes was measured to the nearest 0.1 kg. Body mass
index (BMI) was calculated as the body weight (kg)
divided by the square of the body height (m2). Smoking
status, alcohol drinking, marital status, job title, job
position, and non-occupational physical activity were
self-reported in the lifestyle questionnaire. Job title
was used to create categories for occupational physical
activity; sedentary work included managerial and clerical
jobs, whereas physically active work included child-care,
school lunch cooking, and technical jobs at water, sewer,
and waste treatment facility. Non-occupational physical
activity was expressed as daily minutes spent for walking
or cycling during commute to or from work and weekly
hours engaged in each of five different activities (walking,
low-, moderate-, and high-intensity activities, and
gardening). The sum of time spent for all the non-
occupational activities were expressed in hours per week.
Statistical analyses
Because the association of leptin and ghrelin with
depressive symptoms may not be linear, we used tertile
categories of leptin and ghrelin. Characteristics of study
subjects across tertiles of leptin or ghrelin level and their
trend association were assessed using linear regression
analysis for continuous variables or Mantel-Haenszel
chi-square test for categorical variables. Serum leptin
and ghrelin levels were considerably higher in women
than men, thus we present the data separately. Multiple
logistic regression analyses were used to estimate odds
ratios (ORs) and 95% confidence intervals (CIs) of
depressive symptoms for the tertiles of leptin and
ghrelin levels, taking the lowest tertile as a reference.We adjusted for a range of potential confounding factors,
which were a priori selected with reference to reviews on
risk factor for depression [49,50] as well as our previous
works on folate and ferritin [51,52] . The two participating
offices in the present study are denoted as workplace A
and workplace B. In the first model, we adjusted for
age (year, continuous), and workplace (A or B). In the
second model, we further adjusted for marital status
(married or unmarried), job position (low, medium, or
high), occupational physical activity (active or sedentary),
non-occupational physical activity (0, >0 to <2 hours/week,
or ≥2 hours/week), current smoking (yes or no), alcohol
drinking (yes or no), total energy intake (kcal/day, continu-
ous), BMI (kg/m2, continuous), logarithmic serum ferritin
(μg/L, continuous), and logarithmic serum folate (ng/mL,
continuous). Trend association was assessed by assigning
ordinal numbers 1–3 to tertiles of leptin and ghrelin levels.
The effect modification by sex on the association between
leptin, ghrelin, and depressive symptoms was assessed
using the likelihood ratio test in the full adjusted model.
Two-sided P values <0.05 were regarded as statistically
significant. All analyses were performed using statistical
software Stata version 12.1 (StataCorp, College Station,
Texas USA).
Results
The prevalence of depressive symptoms was 26.5% and
33.3% among men and women, respectively using the
standard cutoff value (CES-D ≥ 16). Mean values of
serum leptin and ghrelin levels were significantly higher
in women than men (mean leptin: men, 1.88 ng/mL,
women, 3.45 ng/mL; mean ghrelin: men, 0.59 ng/mL,
women, 0.82 ng/mL) (P <0.001 for both). In men, the
median and range of leptin (ng/mL) from lowest
through highest tertiles were 0.56 (0.11 − 1.03), 1.36
(1.04 − 1.96), and 3.16 (1.97 − 10.64). The corresponding
values (ng/mL) in women were 0.96 (0.08 − 1.95), 2.95
(1.96 − 3.89), and 5.65 (3.90 − 16.55). With regard to
ghrelin, median and range (ng/mL) from lowest through
highest tertile were 0.32 (0.12 − 0.41), 0.54 (0.42 − 0.72),
and 0.89 (0.73 − 2.84) in men, and were 0.41(0.17 − 0.63),
0.78 (0.64 − 0.92), and 1.20 (0.93 − 3.21) in women.
Subjects’ characteristics according to tertiles of leptin
in men and women are presented in Table 1. Men with
higher leptin levels were more likely to be older and had
higher BMI, but were less likely to be in a low job
position. In women, participants with higher leptin
levels had higher BMI and had a higher energy intake.
Subjects’ characteristics across tertiles of ghrelin in men
and women are presented in Table 2. In both men and
women, subjects with higher ghrelin had lower BMI, but
were more likely to be an alcohol drinker.
The odds ratios for depressive symptoms according to
tertiles of leptin and ghrelin are presented in Table 3.
Table 1 Characteristics of study subjects according to tertiles (T) of leptin (ng/mL)
Men Women
T1 (low) T2 T3 (high) Trend Pa T1 (low) T2 T3 (high) Trend Pa
n 96 96 95 70 70 70
Age (mean ± S.D., year) 42.7 ± 10.6 45.6 ± 11.3 45.8 ± 11.1 0.049 42.3 ± 10.1 41.4 ± 10.1 44.4 ± 10.2 0.24
BMI (mean ± S.D., kg/m2) 21.1 ± 2.3 22.8 ± 1.9 25.8 ± 3.2 <0.01 19.4 ± 2.8 20.9 ± 2.0 23.2 ± 2.8 < 0.01
Workplace (A, %)b 28.1 35.4 32.6 0.50 44.3 11.4 8.6 < 0.01
Married (%) 75.0 84.4 80.0 0.39 72.9 54.3 72.9 0.98
Job position (low, %) 59.4 51.0 44.2 0.04 71.4 64.3 58.6 0.11
Sedentary work (%) 89.6 86.5 93.7 0.35 64.3 74.3 67.1 0.72
Non-job physical activity (≥2 h/week, %)c 51.0 42.7 47.4 0.61 24.3 24.3 28.6 0.56
Current smoker (%) 65.6 57.3 55.8 0.17 4.3 7.1 1.4 0.41
Current alcohol drinker (%) 69.8 70.8 68.4 0.84 45.7 50.0 48.6 0.74
Energy intake (kcal/day) 1921 ± 539 1864 ± 439 1983 ± 580 0.42 1509 ± 383 1562 ± 411 1679 ± 426 0.01
Serum folate (ng/mL) median (IQR) 5.2 (4.3-7.3) 5.5 (4.3-6.7) 5.2 (4.1-6.6) 0.41 6.6 (5.6-8.5) 6.3 (4.9-8.8) 6.3 (5.7-7.6) 0.29
Serum ferritin (μg/L) median (IQR) 123.5 (86.0-184.0) 149.0 (96.6-224.0) 172.0 (105.0-251.0) 0.31 36.1 (12.7-81.4) 39.9 (15.8-77.6) 36.1 (14.1-85.7) 0.98
Abbreviation: BMI body mass index, IQR interquartile range.
aOn the basis of Mantel-Haenszel chi-square test for categorical variables and linear regression analysis for continuous variables, assigning ordinal numbers 1–3 to tertiles of leptin.
bTwo worksites of our study population was denoted as workplace A and workplace B.
cPhysical activity was expressed as the sum of weekly hours spent for sport activity, as well as walking and cycling on commuting to and from work.
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Table 2 Characteristics of study subjects according to tertiles (T) of ghrelin (ng/mL)
Men Women
T1 (low) T2 T3 (high) Trend Pa T1 (low) T2 T3 (high) Trend Pa
n 96 96 95 70 70 70
Age (mean ± S.D., year) 47.0 ± 11.2 43.2 ± 10.6 43.9 ± 11.1 0.052 44.6 ± 9.9 42.5 ± 10.9 41.0 ± 9.4 0.24
BMI (mean ± S.D., kg/m2) 24.3 ± 3.5 23.2 ± 2.9 22.2 ± 2.7 <0.01 22.2 ± 2.9 21.2 ± 2.8 20.1 ± 2.9 < 0.01
Workplace (A, %)b 25.0 31.3 40.0 0.08 24.3 28.6 11.4 0.06
Married (%) 78.1 79.2 82.1 0.49 68.6 64.3 67.1 0.86
Job position (low, %) 50.0 50.0 54.7 0.51 51.4 74.3 68.6 0.03
Sedentary work (%) 84.4 93.8 91.6 0.09 68.6 65.7 71.4 0.72
Non-job physical activity (≥2 h/week, %)c 55.2 32.3 53.7 0.60 24.3 25.7 27.1 0.56
Current smoker (%) 39.6 40.6 41.1 0.84 2.7 1.4 8.6 0.09
Current alcohol drinker (%) 64.6 66.7 77.9 0.046 37.1 51.4 55.7 0.03
Energy intake (kcal/day) 1939 ± 585 1897 ± 534 1933 ± 444 0.93 1622 ± 420 1561 ± 432 1567 ± 385 0.43
Serum folate (ng/mL) median (IQR) 5.3 (4.3 − 6.8) 5.3 (4.3 − 6.7) 5.2 (3.9 − 6.8) 0.43 6.4 (5.4 − 7.3) 6.4 (5.5 − 8.8) 6.5 (5.5 − 8.8) 0.07
Serum ferritin (μg/L) median (IQR) 136.0 (84.7 − 189.5) 153.5 (101.6 − 245.0) 147.0 (90.2 − 211.0) 0.61 28.6 (9.6 − 60.2) 38.6 (16.7 − 89.9) 42.1 (16.8 − 81.4) 0.48
Abbreviation: BMI body mass index, IQR interquartile range.
aOn the basis of Mantel-Haenszel chi-square test for categorical variables and linear regression analysis for continuous variables, assigning ordinal numbers 1–3 to tertiles of ghrelin.
bTwo worksites of our study population was denoted as workplace A and workplace B.
cPhysical activity was expressed as the sum of weekly hours spent for sport activity, as well as walking and cycling on commuting to and from work.
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Table 3 Odds ratios and 95% confidence intervals for depressive symptoms according to tertiles of leptin and ghrelin
Men Women P for
interactiongT1 (low) T2 T3 (high) Trend Pa T1 (low) T2 T3 (high) Trend Pa
Leptin (ng/mL)
Median serum leptin (ng/mL) 0.56 1.36 3.16 0.96 2.95 5.65
CES-D (15/16)
Withb/without depressive symptomsc (n) 26/70 23/73 27/68 27/43 20/50 23/47
Age- and workplace-adjusted OR (95% CI) 1.00 0.89 (0.46 − 1.71) 1.12 (0.59 − 2.12) 0.73 1.00 0.55 (0.26 − 1.16) 0.64 (0.30 − 1.36) 0.27
Multivariable-adjusted OR (95% CI)d 1.00 0.98 (0.48 − 1.99) 1.33 (0.58 − 3.09) 0.52 1.00 0.41 (0.17 − 0.97) 0.47 (0.18 − 1.23) 0.14 0.18
CES-D (18/19)
Withe/without depressive symptomsf (n) 20/76 15/81 19/75 20/50 13/57 17/53
Age- and workplace-adjusted OR (95% CI) 1.00 0.72 (0.34 − 1.51) 0.97 (0.47 − 1.96) 0.92 1.00 0.51 (0.22 − 1.19) 0.75 (0.34 − 1.69) 0.35
Multivariable-adjusted OR (95% CI)d 1.00 0.83 (0.37 − 1.87) 1.28 (0.50 − 3.25) 0.64 1.00 0.34 (0.13 − 0.92) 0.51 (0.18 − 1.47) 0.16 0.21
Ghrelin (ng/mL)
Median serum ghrelin (ng/mL) 0.32 0.54 0.89 0.41 0.78 1.20
CES-D (15/16)
Withb/without depressive symptomsc (n) 28/68 25/71 23/72 20/50 22/48 28/42
Age- and workplace-adjusted OR (95% CI) 1.00 0.83 (0.44 − 1.58) 0.78 (0.40 − 1.50) 0.45 1.00 1.19 (0.57 − 2.46) 1.72 (0.84 − 3.55) 0.14
Multivariable-adjusted OR (95% CI)d 1.00 0.68 (0.34 − 1.38) 0.74 (0.36 − 1.51) 0.40 1.00 1.71 (0.76 − 3.86) 2.69 (1.16 − 6.28) 0.02 0.15
CES-D (18/19)
Withe/without depressive symptomsf (n) 20/76 16/80 19/76 17/53 17/53 19/51
Age- and workplace-adjusted OR (95% CI) 1.00 0.62 (0.29 − 1.29) 0.74 (0.36 − 1.53) 0.41 1.00 1.13 (0.50 − 2.55) 1.35 (0.60 − 3.08) 0.25
Multivariable-adjusted OR (95% CI)d 1.00 0.47 (0.21 − 1.06) 0.79 (0.37 − 1.70) 0.52 1.00 1.45 (0.60 − 3.49) 2.76 (1.71 − 5.37) 0.03 0.22
Abbreviation: OR odds ratio, CI confidence interval.
aBased on multiple logistic regression analysis, with ordinal numbers 1–3 assigned to tertile categories of leptin and ghrelin.
bDefined as a Center for Epidemiologic Studies Depression Scale score of ≥16.
cDefined as a Center for Epidemiologic Studies Depression Scale score of <16.
dAdjusted for age (year, continuous), workplace (A or B), marital status (married or unmarried), job position (low, medium, or high), occupational physical activity (active or sedentary), non-occupational physical activity
(0, >0 to <2 hours/week, or ≥2 hours/week), current smoking (yes or no), alcohol drinking (yes or no), total energy intake (kcal/day), body mass index (kg/m2, continuous), logarithmic serum folate (ng/mL, continuous),
and logarithmic serum ferritin (μg/L, continuous).
eDefined as a Center for Epidemiologic Studies Depression Scale score of ≥19.
fDefined as a Center for Epidemiologic Studies Depression Scale score of <19.
gP value for interaction between sex and adipokines with depressive symptoms was assessed using the likelihood ratio test.
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http://www.biomedcentral.com/1471-244X/14/203Women in the middle and highest tertiles of leptin levels
showed lower odds for depressive symptoms compared
with those in the lowest level, although the trend associ-
ation was not statistically significant (Ptrend = 0.14). In the
multivariable adjusted model, compared with women in the
first tertile of leptin, those in the second and third tertile
had 59% (OR 0.41, 95% CI 0.17-0.97) and 53% (OR 0.47,
95% CI 0.18-1.23) lower odds for depressive symptoms,
respectively. A similar association was observed between
leptin and depressive symptoms, when the presence of
depressive symptoms was defined as CES-D ≥ 19. In
women, the multivariable adjusted ORs (95% CIs) for
depressive symptoms in first, second, and third tertiles
of leptin were 1.00 (reference), 0.34 (0.13-0.92), and 0.51
(0.18-1.47), respectively (Ptrend = 0.16). In men, there
was no association between leptin levels and depressive
symptoms using the two different cut off values of
depressive symptoms.
In multivariable adjusted models, higher ghrelin levels
were associated with increased odds for depressive symp-
toms in women (Ptrend = 0.02) (Table 3). The multivariable
adjusted ORs (95% CIs) of depressive symptoms for the
lowest through highest tertiles of ghrelin levels were 1.00
(reference), 1.71 (0.76-3.86), and 2.69 (1.16-6.28), respect-
ively. Similarly, when another cutoff value for the definition
of depressive symptoms (CES-D ≥19) was used, the ORs
(95% CIs) for lowest through highest tertiles of ghrelin
were 1.00 (reference), 1.45 (0.60-3.49), and 2.76 (1.71-5.38),
respectively, in women (Ptrend = 0.03). In men, ghrelin
levels were not associated with depressive symptoms.
Discussion
In an apparently healthy Japanese working population,
women with higher ghrelin levels had higher odds for
depressive symptoms than those with lower ghrelin
levels, whereas women in the upper two-thirds of leptin
levels had lower odds for depressive symptoms than
those in the lowest third. In men, neither leptin nor
ghrelin was associated with depressive symptoms. To our
knowledge, this is the first study among Asians to examine
the association between leptin and ghrelin levels and
depressive status in the general population.
Our finding regarding leptin is in line with a previous
clinical study [31], wherein leptin levels were significantly
lower in female depressed patients than healthy controls,
but the association was null in men. The present findings
also concur with another study among suicide attempters
[32], reporting that depressed women had lower leptin
levels than non-depressed women, whereas no significant
association was observed in men. As observed previously
[31,32], we also found that women, as compared with
men, had higher levels of leptin. Because we found no
reduction in the odds for men in the highest tertile of
leptin (a level comparable to women in the middle tertileof leptin showing a reduction in the odds for depression),
the gender difference in leptin levels may not account for
the null finding in men. Alternatively, there may be a
gender difference in the relationship between leptin
and depression.
The finding of fewer depressive symptoms in women
with higher levels of leptin is at odds with the results of
two previous population-based studies. In a previous US
study [42], leptin was not associated with depression in
women, but higher leptin was associated with increased
risk of depression in men with high visceral fat. In an
Australian study [41], women with a lifetime history of
depression had elevated levels of leptin, and leptin levels
predicted the subsequent development of de novo
major depressive disorder over five years of follow-up,
independently of BMI. Given that obesity is associated
with inflammation [53], which has been linked to both the
risk for depression [54] and the development of leptin
resistance [55], the positive association observed in
these Western studies may be ascribed to a higher BMI of
the participants. In a Japanese population, which has on
average much lower BMI than Westerners, the association
between leptin and mood disorder may be less likely to be
influenced by such inflammation-depression pathway.
On the basis of contradictory data among epidemiological
studies on the relationship between leptin and depressive
symptoms, Lu et al. [10] suggested that both leptin insuffi-
ciency and leptin resistance might contribute to alterations
of affective status. This could explain, at least in part, the
non-linear relationship between leptin and depressive
symptoms in the present study. We found no further reduc-
tion in the odds for depressive symptoms among women in
the highest tertile of leptin, who had a higher mean BMI
than those in the middle tertile of leptin, suggesting that re-
duced leptin sensitivity may mitigate any possible protective
effects of leptin on depression in this group.
Ghrelin levels were significantly and positively associated
with depressive symptoms among women in the present
study. At variance with our finding, a clinical study reported
that ghrelin level was not associated with depressive
symptoms in women [30]. Likewise, other clinical studies
found no significant difference in ghrelin levels between
patients with major depression and healthy controls
[27,37,38]. Another study reported significantly lower
levels of ghrelin in depressive patients than in healthy
controls [39]. However, in another study, suicide attemp-
ters had significantly higher levels of ghrelin than healthy
controls [40]. Such inconsistency among clinical studies
may be ascribed to the influence of depression on ghrelin
levels or methodological shortcomings, such as small sam-
ple size and the lack of control for potential confounders
including BMI and lifestyle factors. Population-based
studies are needed to explore the association between
ghrelin and depression.
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http://www.biomedcentral.com/1471-244X/14/203A similar association between leptin, ghrelin, and depres-
sive symptoms was observed when the presence of depres-
sive symptoms was defined by two different cutoffs.
Although the cutoff for CES-D ≥ 16 has been widely rec-
ommended, the cut off CES-D ≥ 19 has been recommended
based on a validation study among Japanese workers [48].
Such a higher cutoff is reasonable for Japanese given that
Japanese tend to express their positive emotion in a modest
manner, potentially leading to a higher score on depression
scales [56]. The consistency in relationships between leptin,
ghrelin, and depressive symptoms using two different
cutoffs of CES-D in defining depressive symptoms in our
study strengthens our findings.
Our findings linking depression with higher level of lep-
tin and lower levels of ghrelin seems reasonable given that
leptin treatment improves monoamine neurotransmission
[18,19] and lessens HPA axis [21,22], whereas ghrelin has
opposite effects [24-26]. Because depression often results
in profound alterations in dietary intakes, with either
increased or decreased appetite, the observed differences
in leptin and ghrelin levels between those with and without
depression symptoms may simply reflect such change in
dietary habit. However, this is a less plausible explanation
for the present finding, as we found no significant differ-
ences in energy intake and BMI in subjects with depressive
symptoms compared to those without.
Major strengths of the present study include the high
study participation rate (94%), the exclusion of participants
with history of chronic diseases, including type 2 diabetes,
cardiovascular disease, and cancer, which may alter the
levels of leptin or ghrelin, and the adjustment for potential
cofounding variables. Despite these strengths, our study
had several limitations that warrant mention. Firstly, data
derived from a cross-sectional study cannot shed light on
the direction of the relationship and it is not possible to
determine causality. Secondly, ghrelin and leptin were
measured only a single time point, which limits the
accuracy of the measurement. However, Lee et al. [57]
showed that adipokine levels measured in a single sample
had a high correlation with the mean of the remaining
three seasonal samples. Thirdly, because of the relatively
small sample, statistical power might not have been suffi-
cient to detect a moderate association. Fourthly, our study
population was apparently healthy population and hence
symptoms of depression in our sample were less than one
would observe in clinical populations of patients with
depression. Finally, our study was conducted in selected
municipal offices, thus the findings may not be generalizable
to the whole population of Japanese adults.
Conclusions
In conclusion, this study show that higher ghrelin levels
are associated with increased prevalence of depressive
symptoms in women. Longitudinal studies with largesample size, assessments of serum leptin and ghrelin at
multiple times point, and follow-up assessments for
clinical depression are needed to confirm the present
findings.
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